99 related articles for article (PubMed ID: 22324947)
1. Frequency of anemia of inflammation in patients with ankylosing spondylitis requiring anti-TNFα drugs and therapy-induced changes.
Niccoli L; Nannini C; Cassarà E; Kaloudi O; Cantini F
Int J Rheum Dis; 2012 Feb; 15(1):56-61. PubMed ID: 22324947
[TBL] [Abstract][Full Text] [Related]
2. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
3. Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: a real-life experience.
Can M; Aydın SZ; Niğdelioğlu A; Atagündüz P; Direskeneli H
Int J Rheum Dis; 2012 Dec; 15(6):526-30. PubMed ID: 23253235
[TBL] [Abstract][Full Text] [Related]
4. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
Gadsby K; Deighton C
Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137
[TBL] [Abstract][Full Text] [Related]
6. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy.
Prince DS; McGuigan LE; McGirr EE
Int J Rheum Dis; 2014 Feb; 17(2):165-72. PubMed ID: 24576272
[TBL] [Abstract][Full Text] [Related]
7. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.
Spadaro A; Lubrano E; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Perrotta FM; Olivieri I; Punzi L; Salvarani C
Rheumatology (Oxford); 2013 Oct; 52(10):1914-9. PubMed ID: 23878312
[TBL] [Abstract][Full Text] [Related]
8. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
[TBL] [Abstract][Full Text] [Related]
9. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade.
van Eijk IC; Peters MJ; Serné EH; van der Horst-Bruinsma IE; Dijkmans BA; Smulders YM; Nurmohamed MT
Ann Rheum Dis; 2009 Mar; 68(3):362-6. PubMed ID: 18390569
[TBL] [Abstract][Full Text] [Related]
10. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers.
Iervolino S; Di Minno MN; Peluso R; Lofrano M; Russolillo A; Di Minno G; Scarpa R
J Rheumatol; 2012 Mar; 39(3):568-73. PubMed ID: 22247361
[TBL] [Abstract][Full Text] [Related]
11. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass.
Yazici S; Yazici M; Erer B; Erer B; Calik Y; Bulur S; Ozhan H; Ataoglu S
Platelets; 2010; 21(2):126-31. PubMed ID: 20050759
[TBL] [Abstract][Full Text] [Related]
12. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MÁ
Clin Exp Rheumatol; 2013; 31(6):913-8. PubMed ID: 23981480
[TBL] [Abstract][Full Text] [Related]
13. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
[TBL] [Abstract][Full Text] [Related]
14. Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.
Korkosz M; Gąsowski J; Leszczyński P; Pawlak-Buś K; Jeka S; Siedlar M; Grodzicki T
Scand J Rheumatol; 2014; 43(1):43-8. PubMed ID: 24447112
[TBL] [Abstract][Full Text] [Related]
15. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.
Depalma RG; Hayes VW; Chow BK; Shamayeva G; May PE; Zacharski LR
J Vasc Surg; 2010 Jun; 51(6):1498-503. PubMed ID: 20304584
[TBL] [Abstract][Full Text] [Related]
16. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.
van Eijk IC; de Vries MK; Levels JH; Peters MJ; Huizer EE; Dijkmans BA; van der Horst-Bruinsma IE; Hazenberg BP; van de Stadt RJ; Wolbink GJ; Nurmohamed MT
Arthritis Rheum; 2009 May; 60(5):1324-30. PubMed ID: 19404933
[TBL] [Abstract][Full Text] [Related]
17. Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients.
Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2242-4. PubMed ID: 17889151
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of etanercept for treating ankylosing spondylitis].
Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
[TBL] [Abstract][Full Text] [Related]
19. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
[TBL] [Abstract][Full Text] [Related]
20. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
